Table 1.

Clinical characteristics of patients with second primary breast carcinoma and with those of breast metastases.

		Second primary breast carcinoma (n=123), n (%)	Breast metastases (n=17), n (%)	P value
Gender	Male	2 (1.63%)	0 (0%)	1.000
	Female	121 (98.37%)	17 (100%)
Age	<45	19 (15.45%)	7 (41.18%)	0.018
	≥45	104 (84.55%)	10 (58.82%)
	Median	55	44
	Range	29-87	27-85
Size of breast mass (cm)	<2	36 (29.27%)	1 (5.88%)	0.094
	2-5	77 (62.60%)	14 (82.35%)
	>5	10 (8.13%)	2 (11.76%)
ER/PR status	Positive	94 (76.42%)	1 (5.88%)	<0.001
	Negative	29 (23.58%)	16 (94.12%)
HER-2 status	Positive	37 (30.08%)	2 (11.76%)	0.153
	Negative	86 (69.92%)	15 (88.24%)
Smoking history	Yes	8 (6.50%)	2 (11.76%)	0.349
	No	115 (93.50%)	15 (88.24%)
Family history of cancers	No	71 (57.72%)	12 (70.59%)	0.431
	Yes	52 (42.28%)	5 (29.41%)
	Breast cancer	14 (11.38%)	1 (5.88%)
	Others	38 (30.89%)	4 (23.53%)
History of radiotherapy or chemotherapy	Yes	58 (47.15%)	13 (76.47%)	0.023
	No	65 (52.85%)	4 (23.53%)
Symptoms	No	28 (22.76%)	1 (5.88%)	0.197
	Yes	95 (77.24%)	16 (94.12%)
	Lump (s)	86 (69.92%)	16 (94.12%)
	Nipple discharge	7 (5.69%)	0 (0%)
	Diffuse swelling	2 (1.63%)	0 (0%)
Distant metastasis	Yes	1 (0.81%)	15 (88.24%)	<0.001
	No	122 (99.19%)	2 (11.76%)
Interval time (months)	Synchronous	55 (44.72%)	8 (47.06%)	0.856
	Metachronous	68 (55.28%)	9 (52.94%)
	Mean	51.6	19.8
	Range	0-436	0-122
Stage of first malignancy	I/II	88 (71.54%)	2 (11.76%)	<0.001
	III/IV	35 (28.46%)	15 (88.24%)
Age at diagnosis of first malignancy	<60	33 (26.83%)	13 (76.47%)	<0.001
	≥60	90 (73.17%)	4 (23.53%)
	Mean	53.0	48.5
	Range	25-86	25-75

ER: Estrogen receptor, PR: Progesterone receptor, HER-2: Human epidermal growth factor receptor 2.